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Objectives: Poorly controlled hypertension (HTN) is extremely prevalent and if left 59 
unchecked, subclinical hypertensive heart disease (SHHD) may ensue leading to 60 
conditions such as heart failure (HF). To address this, we designed a multidisciplinary 61 
program to detect and treat SHHD in a high-risk, predominantly African American 62 
community. The primary objective of this study was to determine the cost effectiveness 63 
of our program. 64 
 65 
Methods: Study costs associated with identifying and treating patients with SHHD were 66 
calculated and a sensitivity analysis was performed comparing the effect of four 67 
parameters on cost estimates. These included prevalence of disease, effectiveness of 68 
treatment (regression of SHHD, reversal of left ventricular hypertrophy [LVH] , or blood 69 
pressure [BP] control as separate measures), echocardiogram costs, and participant 70 
time/travel costs. The parent study for this analysis was a single center, randomized 71 
controlled trial comparing cardiac effects of standard and intense (<120/80 mm Hg) BP 72 
goals at 1 year in patients with uncontrolled HTN and SHHD. A total of 149 patients 73 
(94% African American) were enrolled, 133 (89%) had SHHD, 123 (93%) of whom were 74 
randomized, with 88 (72%) completing the study. Patients were clinically evaluated and 75 
medically managed over the course of one year with repeated echocardiograms. Costs of 76 
these interventions were analyzed and, following standard practices, a cost per quality-77 
adjusted life year (QALY) less than $50,000 was defined as cost effective.  78 
 79 
Results: Total costs estimates for the program ranged from $117,044 to $119,319. Cost 80 
per QALY was dependent on SHHD prevalence and the measure of effectiveness but not 81 
input costs. Cost effectiveness (cost per QALY less than $50,000) was achieved when 82 
SHHD prevalence exceeded 11.1% for regression of SHHD, 4.7% for reversal of LVH, 83 
and 2.9% for achievement of BP control. 84 
 85 
Conclusions: In this cohort of predominantly African American patients with 86 
uncontrolled HTN, SHHD prevalence was high and screening with treatment was cost 87 
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programs such as this can be a cost effective mechanism to mitigate the cardiovascular 89 
consequences of HTN in ED patients with uncontrolled BP. 90 
INTRODUCTION 91 
Poorly controlled hypertension (HTN) is extremely prevalent in the U.S 1-6, with a 92 
disproportionally high disease burden existing among African-Americans, putting them at 93 
greater risk for poor cardiovascular outcomes such as stroke, myocardial infarction, 94 
chronic kidney disease, and heart failure. 1,7-11 Recommendations for therapy are well 95 
defined by the International Society of Hypertension in Blacks (ISHIB)12 and in the 96 
recent Joint National Committee reports on HTN.13,14 However, due to factors that are 97 
difficult to overcome (therapeutic inertia, poor adherence to therapy, socio-economic 98 
barriers and patient understanding of disease state), achieving blood pressure (BP) control 99 
remains a challenge. 1,13,15-21 100 
For patients with chronic but uncontrolled HTN, cardiac remodeling is a near 101 
universal process that is associated with increased cardiovascular risk as it progresses. 102 
Despite this, underlying heart disease (HD) is typically not detected (or even screened 103 
for) until advanced remodeling is present and symptoms manifest 9,11,22-24, leaving 104 
clinicians with fewer options to prevent adverse events. Early identification of subclinical 105 
hypertensive heart disease (SHHD) and appropriate control f BP have become important 106 
steps in secondary cardiovascular disease prevention (especially for HF) 11,25-28. Although 107 
some perceive that screening of asymptomatic patients provides no long-term benefit to 108 
morbidity 28-31, compelling arguments have been made for the utility of screening 109 
activities in communities that are predominately urban, African-American, and where 110 
limitations to healthcare access prompts heavy reliance on the emergency department 111 
(ED) for primary care. 11,32-35 Increasing prevalence of the target condition is often tied to 112 
cost-effectiveness of such approaches and, in the case of SHHD, has direct implications 113 
for intensification of antihypertensive therapy. 36 114 
 115 
The development of preventable secondary complications of SHHD lead to substantial 116 
increases in morbidity, mortality and health care costs. 37 Multiple studies have 117 
demonstrated that uncontrolled HTN is a significant risk factor for the progression of 118 
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disproportionate burden of hypertensive heart disease in urban, African American 120 
populations, the primary objective of this study was to assess the cost effectiveness of a 121 
multidisciplinary screening program designed to identify and treat SHHD among ED 122 
patients with elevated BP. 123 
 124 
METHODS 125 
Study Design and Setting 126 
This cost-effectiveness analysis was an a priori aim included as part of a grant 127 
funded prospective, randomized controlled clinical trial (NCT00689819) designed to 128 
compare the effects of two BP targets (control, BP <140/90 mm Hg [<130/80 mm Hg if 129 
diabetes or chronic kidney disease was present] and intervention, which had a singular 130 
target of <120/80 mm Hg) on reverse remodeling for patients with SHHD. Details of the 131 
study design, including SHHD determination and regression, have been previously 132 
published.38  A convenience sample of patients who presented to a single cent r ED 133 
located in Detroit, Michigan, where the population is 83% African-American was 134 
enrolled between November 2008 and April  2010.  Enrolled patients were evaluated at 135 
three-month intervals over the course of one year in a single HTN clinic. Care was 136 
delivered by a multidisciplinary team including an ED physician, a HTN specialist 137 
experienced with HTN in our patient population, a physician’s ssistant (PA), anurse 138 
practitioner (NP), research assistants, and clinic office staff. All care-related expenses, 139 
including transportation, telephone reminders, medications, and tests were provided free 140 
of charge to all the participants. The institutional review board approved this study and 141 
all subjects provided written informed consent. 142 
 143 
Selection of Participants 144 
Study participants were recruited from a tertiary, academic medical center’s ED, 145 
which treats over 90,000 patients each year.  Over a 17 month period, individuals 35 146 
years of age and older who presented with an initial BP  >140/90 mm Hg were identified 147 
using the facility’s electronic medical record (FirstNet byCerner Corp.; Kansas City, 148 
MO). For inclusion, patients were required to have a repeat BP > 140/90 mm Hg, and 149 
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Scale). Those with acute illness requiring hospitalization, history of previously diagnosed 151 
coronary artery disease or HF, presenting symptoms (i.e. dyspnea, chest pain) potentially 152 
attributable to hypertensive heart disease, and those being actively followed and/or 153 
treated by PCP were excluded.11,38,39  Patients who met these criteria were brought back 154 
for a follow-up screening echocardiogram in our outpatient HTN clinic.  155 
In total, 160 individuals met initial inclusion criteria, 149 of whom returned for a 156 
subsequent screening echocardiogram.  All  echocardiograms were performed and 157 
detailed history obtained for screened participants within one week. All participants with 158 
SHHD, defined by presence of left ventricular (LV) hypertrophy (LV mass ≥ 48 g/m2.7 in 159 
males or ≥ 45 g/m2.7 in females), LV systolic dysfunction (ejection fraction < 50%), or 160 
diastolic dysfunction (combination of parameters based on validated criteria of LV 161 
stiffness and relaxation) were andomized into either control or intensive therapy arms.11 162 
  163 
 164 
Randomized participants were seen at baseline (initial visit) and 3, 6, 9, and 12-165 
month intervals. A standard BP measurement protocol was utilized. A trained research 166 
assistant, using appropriately sized oscillometric brachial cuff, performed three BP 167 
measurements with the patient in a seating position and their arms resting comfortably at 168 
heart level.  The average reading of the three m asurements was used to determine the BP 169 
reading recorded for that clinic visit. A multidisciplinary group of PAs and NPs then 170 
titrated antihypertensive therapy as needed, according to study group assignment. During 171 
each clinic visit, participants were educated about the importance of medication 172 
adherence and all received telephone reminders for pending follow up appointments. 173 
Additionally, to help ensure compliance, all medication costs were paid for using study 174 
funds. Echocardiograms, all interpreted by a single board-certified cardiologist blinded to 175 
patient information and study group, were repeated at the 12-month visit. SHHD 176 
regression was the absence of LVH and systolic or diastolic dysfunction on repeat 177 
imaging. Because LVH is such an important consequence of HTNand contributor to 178 
important outcomes such as HF development, we also evaluated reversal of LVH (i.e., 179 
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Cost Analysis 182 
Total costs of the program (Table 1) were calculated by adding the cost of 183 
medications (based on purchase price from our outpatient pharmacy), laboratory tests 184 
(based on hospital research pricing), clinic activities (based on proportional space and 185 
personnel costs), echocardiograms (based on echocardiographic technician time), and 186 
participant time and travel. Time and travel costs were obtained through a survey and 187 
mean values of respondents were used to estimate a base case value of $22.72 +/- $14.36 188 
per person. When data were missing, values for time and travel costs were imputed three 189 
different ways, separated by participants who did and did not complete the study: as zero 190 
(i.e., assumption of no cost), as the cohort median, and as the cohort mean. Based on this, 191 
low, median, and high total costs were estimated.  192 
To evaluate cost effectiveness, costs per quality-adjusted life year (QALY) were 193 
calculated. This approach is widely accepted and QALY’s have long been used to guide 194 
healthcare resource allocation. 40 A threshold cost of $50,000 per QALY is the traditional 195 
benchmark for determining the value of care. Therefore, values at or below this were 196 
adopted in our study as the measure of cost-effectiveness. 41-43 The  cost per QALY was 197 
modeled by the following mathematical equation, where 0.87 and 0.71 are used as 198 
standard utility values44 assigned to patients for whom chronic HF (the most likely 199 





We based the probability of treatment effectiveness on preventing HF using three 205 
measures: regression of SHHD, reversal of LVH, and achievement of BP control. For 206 
purposes of this analysis, achievement of BP control was based on study randomization 207 
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outcome for each of these at 100%, 50%, and 25% for the low, median and high end of 209 
the calculated program cost (Table 2) then calculated the cost per case prevented, cost per 210 
QALY where HF would have been prevented and cost per QALY where HF would have 211 
developed. The variance levels for probabilities were selected to impart large, medium, 212 
and small impacts on the outcomes of interest.  213 
Sensitivity analyses were then performed for each of our three treatment 214 
effectiveness measures, comparing the effect of disease prevalence, echocardiogram 215 
costs, and time/travel costs on cost per QALY using a base case that included the 216 
prevalence of SHHD in our population, the proportion achieving the desired treatment 217 
effect for each measure, and a projected treatment effectiveness of 100% for SHHD and 218 
LVH regression, and 50% for BP control. Medicare reimbursement rates were used to 219 
calculate adjusted total costs as influenced by changing echocardiogram costs, based on 220 
CPT code 93306 using national average global payments for 2013, and 2015, along with 221 
proposed future rates (Table 3). 45 Tornado plots were constructed, representing the 222 




Of the 149 subjects enrolled, 133 (89.3%) had SHHD, 123 (control n=65, 227 
intervention n=58) were randomized, and 88 (control n=45, intervention n=43) completed 228 
the entire study protocol. The study population was mostly female (66%), and African-229 
American (95%), with a mean age was 49 years of age. The majority of patients (82.9%) 230 
had been previously diagnosed with HTN, only 28 (23%) of whom were on prescribed 231 
medication at baseline, and had carried the diagnosis, on average, treated for 8.8 (SD = 232 
8.6) years. At initial screening in the ED, patients had an average systolic BP (SD) of 233 
182.5 (23.3) mm Hg and an average diastolic BP (SD) of 104.8 (12.3) mm Hg.  At 234 
randomization following the screening echocardiogram, verage systolic BP (SD) was 235 
151.2 (24.1) mm Hg and average diastolic BP was 97.2 mm Hg (15.8). Of the 88 patients 236 
that completed therapy, 10 (11%) achieved SHHD regression, 20 (23%) experienced 237 
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Total estimated costs of the program (Table 1) ranged from $117,044 to 239 
$119,319. As shown in Table 2, the program was cost effective (cost per QALY < 240 
$50,000) under all circumstances, except when the projected effectiveness of SHHD 241 
regression was < 25% (Table 3). That is to say, our approach would be cost effective if 242 
the patient has a 25% or greater probability of preventing HF with any of our treatment 243 
effectiveness measures (SHHD regression, LVH regression or BP control), across a range 244 
of cost assumptions. The cost per QALY for all three treatment effectiveness measures 245 
was consistently below the $50,000 mark when assessing cost per case prevented and 246 
cost per case where HF would have been prevented. 247 
Sensitivity analyses demonstrated that for each of the three measureable treatment 248 
effects, only prevalence of SHHD moves the overall cost per QALY above the $50,000 249 
mark. Specifically, overall cost per QALY exceeded $50,000 only at prevalence rates 250 
below 11.1% for SHHD regression, 4.7% for LVH reversal, and 2.9% for BP control 251 
(Figure). 252 
  253 
DISCUSSION 254 
 In this study of hypertensive ED patients, we found that a multidisciplinary 255 
program focused on detection and treatment of SHHD was cost effective across a range 256 
of cost assumptions. This is important because SHHD is a meaningful point where 257 
intervention can prevent potential life-threatening conditions. 12-14  However, for many 258 
with HTN, especially African Americans in underserved communities, heart disease will  259 
not be detected until advanced stages, limiting options for secondary or even tertiary 260 
prevention. 9,11,22-24 While no one would suggest that ED physicians assume primary 261 
responsibility for the management of SHHD, in settings similar to ours where SHHD is 262 
likely to be prevalent, it is reasonable for the ED to play an active role in screening and 263 
referral.  This process could include no more than BP readings and referral for a follow 264 
up echocardiogram. Blood pressure readings are a routine measure taken as part of an ED 265 
patient visit and do not add to the total cost of care. Although echocardiograms are 266 
relatively expensive, not readily available in many EDs, and require (as of now) a 267 
dedicated technician and physician to read the results, they are superior to 268 
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Whether actual prevalence of disease in other communities will approach what we 270 
found in this study (89.3%) is unclear.  Levy et al previously showed that within a similar 271 
population – underserved African American, hypertensive ED patients –the prevalence of 272 
underlying SHHD is close to 90%.11 The prevalence of SHHD in other patient 273 
populations with HTN has not been well described; however, existing studies suggest it 274 
broadly ranges between 0.9 to 50%. 10,11,47-51  Given that the highest calculated 275 
prevalence rate when cost per-QALY exceeds the $50,000 mark in our data is ~11%, it is 276 
likely that a similar program would remain cost effective in the majority of other 277 
locations. It is important to note that for many disease states, the cost effectiveness of 278 
screening is mutually exclusive from that of treatment. However, for the purposes of our 279 
study, no distinction was made between the cost of screening and the cost of treatment, as 280 
we sought to evaluate a program aimed at reducing the consequences of SHHD on an at-281 
risk population – a process that involves both detection and on-going management. To 282 
that end, we chose prevention of HF as the desired end-point of treatment and constructed 283 
our cost effectiveness models using HF as the outcome of interest. We did so because, of 284 
all the consequences associated with SHHD, HF is the most tightly linked overall and one 285 
that disproportionately affects African Americans.52 Moreover, prevention of HF through 286 
more comprehensive upstream screening for SHHD and intervention when present has 287 
become an area of increasing emphasis. 53 288 
Based on our sensitivity analysis, the true cost-effectiveness of our approach to 289 
diagnosis and treatment of SHHD likely sits between $20,000 and $30,000 per year – a 290 
figure that is similar to recently published data by Moise et althat found more intensive 291 
BP control to be cost effective at <$50,000 per QALY for management of HTN, 292 
particularly in patients with cardiovascular disease, chronic kidney disease, and a 10-year 293 
CVD risk >15%. 43 In a recent perspective piece, Neumann et al. argue that the $50,000 294 
per QALY measure may indeed be too low.41 As part of their analysis, they looked at 295 
cost-effectiveness thresholds referenced by authors from 1990-2012. A majority of the 296 
studies reference $50,000 as the most widely used benchmark,43,54 with $100,000 being 297 
the second most popular value. Braithwaite et al further suggest that a range between 298 
$95,000 and $264,000 per life-year saved should be considered when evaluating impact 299 
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QALY was measured to be $62,000.56 Although the usefulness of the $50,000 benchmark 301 
has been questioned, and many other benchmarks have been proposed, the fact remains 302 
that no one measure is appropriate in all decision contexts.41 We chose to adopt the 303 
$50,000 benchmark for our study because we thought it to be consistent with the 304 
economic reality of our study demographic. Using higher thresholds would only provide 305 
further evidence to support the cost effectiveness of ur approach, as there were few 306 
scenarios where sensitivity analysis exceeded the $50,000 mark, and none that were 307 
greater than $62,000.  308 
Problems with therapeutic inertia, poor adherence, socio-economic challenges to 309 
self-care, and low disease-specific knowledge are known to effect HTN control.1,13,15-21. 310 
Accordingly, throughout the study, participants periodically filled out questionnaires 311 
aimed at accurately gauging, among other things, their time and travel costs. In analyzing 312 
responses, a majority indicated distance-to-travel to receive care as an important factor in 313 
their adherence and follow-up.  As travel did not affect cost effectiveness in our study, 314 
paying for this and other potential barriers to follow up for chronic HTN as part of a 315 
broad risk reduction program might be reasonable to consider.  316 
 317 
LIMITATIONS  318 
Several limitations to our study exist. This was a single center trial with a limited 319 
number of subjects, over a relatively short time period, an  this did not allow us to study 320 
cardiovascular outcomes over a longer piod of time. The patient population was 321 
predominantly low-income and African American with poor access to primary medical 322 
care, making our results more difficult to apply across different demographic populations. 323 
However, this is a representative sample from a high risk, underserved and 324 
underrepresented population. As has been established previously, prevalence of 325 
cardiovascular disease is exceedingly high within this demographic and SHHD is the 326 
only factor that determines the cost effectiveness of our treatment model, suggesting that 327 
our data are, at the least, applicable to similar high-risk populations. This study also had a 328 
high dropout rate in both control and intervention groups (28% and 24%; respectively) 329 
which was not unexpected considering the study population and how these at-risk 330 
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Another limitation is that the design of our mathematical model to determine 332 
QALY did not assign hazard ratios to measure regression versus non-regression of end-333 
stage disease.  We believe that this would have led to a more accurate assessment of HF 334 
progression. Additionally, the increased costs associated with developing HF – i.e. 335 
hospitalizations, interventions, loss of productivity, etc. – were not added to the equation 336 
except for in the adopted utility factors. It can be argued that by not including such data, 337 
the development of HF has little impact on the cost effectiveness of our program. 338 
However, we believe that addressing specific outcomes is not essential in building a 339 
strong argument for intervention. Many different adverse consequences are expected as a 340 
result of uncontrolled HTN and utility measures adopted are the most productive way to 341 
represent the broad nature of possible outcomes. Finally, we assigned just one-life-year 342 
gained, which may be under-representing the actual benefits of disease regression. 343 
However, had we used a lengthier time-measure, our results would have only been 344 
further validated. 345 
 Finally, this is a cost-effectiveness study, rather than one that measures (patient 346 
specific) willingness to pay for treatment.  Such an investigation was beyond the scope of 347 
this study but may merit future research. 348 
 349 
CONCLUSIONS 350 
 Our approach to screen for and treat SHHD among urban ED patients with 351 
elevated BP proved to be cost effective across a range of cost, and treatment effectiveness 352 
assumptions. The prevalence of SHHD was particularly high in our predominantly 353 
African American cohort, many of whom utilize the ED for primary care, suggesting that 354 
multidisciplinary programs designed to prevent cardiovascular complications of HTN 355 
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Tables and Figures 522 
 523 
Table 1. Total costs of program with imputed values for missing values of time and 524 
travel costs  525 
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 527 
Table 2. Program cost estimates based on projected disease probability of outcome.  528 
Cost per case prevented, cost per QALY where HF would have been prevented, and cost 529 
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successful outcomes (100%, 50%, 25%) for the low, median and high end of the 531 
calculated program cost.  532 
 533 
 

















100% 50% 25% 
 
100% 50% 25% 
 







$3,259 $6,519 $13,038  
 
$3,320 $6,639 $13,279  
 




$10,104  $20,209  $40,418  
 
$10,291  $20,582  $41,165  
 




$5,052 $10,104  $23,409  
 
$5,146 $10,291  $23,782  
 
$5,166 $10,332  $23,864  
 






$3,747 $7,493 $14,986  
 
$3,816 $7,632 $15,236  
 




$11,614  $23,228  $46,457  
 
$11,829  $23,658  $47,316  
 




$5,807 $11,614  $26,907  
 
$5,914 $11,829  $27,336  
 
$5,938 $11,876  $27,430  
 





$4,591 $9,182 $18,363  
 
$4,676 $9,351 $18,703  
 




$14,232  $28,463  $56,926  
 
$14,495  $28,989  $57,978  
 
$14,552  $29,104 $58,208  
 LVH Regression   $7,116 $14,232  $32,970    $7,249 $14,495  $33,496    $7,276 $14,552  $33,611  




Table 3. Adjusted total costs based on variable echocardiogram costs.538 
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 Cost for 149 screened + 


























  High $153,318   $130,803   $144,075 
* Difference = (Cost for screened + completed therapy) - $29,517 (from Table 1) 
   539 
 540 
 541 
Figure Legend 542 
 543 
 544 
Figure 1. Cost per QALY for people achieving BP control, reversal of LVH, and 545 
regression of SHHD. Only prevalence decreases the cost per QALY below the $50K 546 
mark, which occurs at a prevalence of >2.9% for BP control, >4.7% for LVH regression, 547 
and >11.1% for SHHD regression.  Note: Travel cost data are hidden by the Y-axis. 548 
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